1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Curexo Inc.

Curexo Inc.

060280.KQ
Curexo Inc.KR flagKOSDAQ
11,440.00
KRW
-360.00
- -
470.07BMarket Cap
Curexo Inc.
060280.KQ
(KOSDAQ)

Recent

price

11,440.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
210.62
1,519.87
947.81
1,114.42
935.15
985.29
1,075.88
1,163.25
1,037.88
1,030.92
1,131.4
1,279.16
1,795.27
1,801.04
1,350.57
1,801.79
1,718.25
Revenue per Share
-385.66
-179.3
-509.45
-267.58
-388.51
-336.51
-49.23
-586.58
-901
-777
12
-70
-84
-120
-213
67
51.77
Basic EPS, GAAP
-527.19
-536.25
-825.72
-552.21
-792.32
-1,076.28
-1,447.78
-76.55
-538.64
-162.91
-67.58
-285.37
-376.32
69.09
11.31
-332.93
-170.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1,663.37
-1,297.5
-1,581.59
-1,720.66
-2,106.94
-2,444.81
-1,580.51
-2,087.19
-2,698.33
-3,427.18
-3,264.65
-3,455.08
-3,191.64
-2,956.81
-3,125.34
-3,037.88
-3,031.61
Book Value per Share
943.5
1,140.28
1,712.4
1,063.12
314.83
1,436.96
2,543.39
1,996.18
1,914.18
1,175.81
1,131.63
1,207.45
2,228.94
2,462.16
2,255.63
2,308.56
2,363.92
Tangible Book Value per Share
19
22
26
28
28
28
28
29
33
33
35
33
36
40
41
41
41
Basic Weighted Avg Shares
4,021
33,888
24,281
31,091
26,138
27,530
30,061
33,484
33,890
34,388
39,282
42,795
64,991
72,882
55,531
74,532
70,918
Sales/Revenue/Turnover
-292.48
-15.34
-58.41
-43.21
-80.4
-89.47
-134.36
1.66
-11.34
-12.55
1.32
-4.25
1.71
1.56
-10.48
3.17
0.85
Operating Margin (%)
2,282
1,349
592
792
1,281
1,908
3,191
308
528
669
642
983
1,248
1,592
2,166
2,785
2,767
Depreciation Expense
-7,362
-3,998
-13,051
-7,465
-10,859
-9,402
-1,375
-16,885
-29,420
-25,918
417
-2,342
-3,041
-4,856
-8,758
2,771
2,137
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.52
- -
- -
- -
- -
2.1
1.44
Effective Tax Rate (%)
-183.11
-11.8
-53.75
-24.01
-41.55
-34.15
-4.58
-50.43
-86.81
-75.37
1.06
-5.47
-4.68
-6.66
-15.77
3.72
3.01
Profit Margin (%)
13,086
45,624
39,573
26,096
3,992
35,008
11,683
14,794
36,335
33,402
35,655
32,200
59,363
85,898
80,006
82,918
84,046
Working Capital
- -
23,805
107
118
- -
- -
- -
- -
- -
59
153
82
129
1,488
974
452
269
LT Debt
23,344
32,395
49,481
35,086
13,941
52,187
73,080
70,691
70,029
43,980
44,795
42,902
81,681
100,429
93,381
96,249
98,281
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.16
- -
- -
- -
- -
2.41
0.61
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.39
- -
- -
- -
- -
-2.27
-1.77
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
673
714
722
LT Borrowings
- -
- -
- -
LT Finance Leases
549
452
269
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
- -
Market Capitalization
338,926
529,852
603,004

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
89,649
87,129
89,388
Cash, Cash Equivalents & STI
25,647
20,007
22,046
Accounts Receivable, Net
20,636
24,938
26,435
Inventories
40,908
39,893
37,161
Total Current Liabilities
7,990
4,211
5,343
Payables & Accruals
- -
- -
- -
ST Debt
673
714
722
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.56%
21.03%
3.07%
Free Cash Flow
-240.34%
-583.12%
-3,061.32%
Net Income, GAAP
37.9%
-124.77%
-131.65%
Sales/Revenue/Turnover
12.08%
16.67%
34.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,942
13,513
13,240
14,837
55,531
2025
19,709
16,795
17,228
20,800
74,532
2026
16,095
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9
-35
-38
- -
-213
2025
27
-21.66
20.04
- -
67
2026
11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Miral Dental Clinics Co. (9604.SR)
Basma Adeem Medical Co. (9626.SR)
Aurinia Pharmaceuticals Inc. (AUP.TO)
Prevest Denpro Limited (PREVEST.BO)
Raaj Medisafe India Limited (RAAJMEDI.BO)
Orthometrix, Inc. (OMRX)
Business
Curexo Inc. engages in the development, manufacture, and sale of advanced medical robots and related medical devices primarily in South Korea and internationally. The company operates through three main divisions: Medical Robot, Implant, and Trading. Its core products include surgical robots such as CUVIS-joint, an artificial joint surgery robot platform; CUVIS-spine, a navigation-based spine surgery robot; and Morning Walk S200, a gait rehabilitation robot system. It also produces the InMotion Arm robotic rehabilitation device for upper limb recovery and manufactures as well as markets artificial joint prostheses. Curexo supplies medical devices to hospitals and agencies domestically and globally. Founded in 1992 and headquartered in Seoul, South Korea, the company has expanded its geographic reach into new overseas markets such as Japan, Taiwan, Indonesia, Malaysia, Pakistan, and India, stabilizing its international revenue base. In recent years, Curexo has made significant strategic advances to accelerate global market penetration. In 2024, it obtained regulatory approvals and manufacturing licenses allowing it to commercialize its core products in Japan and India and is pursuing U.S. FDA and European CE certifications for its CUVIS-joint platform, including hip surgery applications. The company has formed strategic partnerships including a distribution agreement with THINK Surgical to co-commercialize the CUVIS-Joint platform outside THINK's distribution territories, especially targeting the U.S. and Vietnam markets. Curexo also partnered with KYOCERA Group for exclusive distribution in Japan and collaborated with Microsoft to integrate artificial intelligence and augmented reality technologies to enhance surgical robot capabilities. The company achieved strong financial performance with 80% growth in medical robot revenue in 2024, turned profitable in Q3 2025 with operating profit of KRW 9.7 billion, and continues investing in R&D to maintain leadership in surgical robot and rehabilitation device development. Curexo leverages its robotic platforms to cater to degenerative arthritis and spinal disorder treatments and rehabilitation, providing precision surgical solutions and recovery aids, with a focus on enhancing surgical accuracy, user convenience, and patient outcomes. Its medical robot systems support knee and hip joint replacements, spine surgeries, and rehabilitation therapies. The company’s ongoing strategic expansion, diversified product portfolio, and technological innovation position it as a leading global medical robotics company serving hospitals and healthcare providers worldwide.